Loading
NASDAQHealthcareMedical - Devices
Latest quote
$2.23
+$0.03 · +1.36%
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
Previous close
$2.23
+$0.03 · +1.36%
Pre-market
$2.25
+$0.02 · +0.90%
Sep 8, 4:00 AM ET
Regular session · ET · Market data may be delayed.
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
Day range
Current $2.23
52-week range
Current $2.23
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
52
Fair Value
Sentiment
42
Mixed
Risk
70
High Risk
Momentum
16
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
Day range
Current $2.23
52-week range
Current $2.23
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.38M USD | 3.29M USD | 3.23M USD | 3.09M USD | 4.14M USD |
| Cost of goods sold | 2.15M USD | 1.84M USD | 1.93M USD | 1.64M USD | 1.94M USD |
| Gross profit | 1.23M USD | 1.45M USD | 1.3M USD | 1.45M USD | 2.2M USD |
| Research and development | 7.43M USD | 7.1M USD | 8.27M USD | 9.12M USD | 5.88M USD |
| Selling, general, and administrative | 8.89M USD | 10.05M USD | 8.6M USD | 9.06M USD | 6.04M USD |
| Operating expenses | 16.32M USD | 17.15M USD | 16.88M USD | 18.18M USD | 11.92M USD |
| Interest income | 37K USD | 378K USD | 924K USD | — | — |
| Depreciation and amortization | 295K USD | 332K USD | 323K USD | — | — |
| Operating income | −15.09M USD | −15.7M USD | −15.58M USD | −16.74M USD | −9.72M USD |
| Net income | −15.06M USD | −15.32M USD | −14.65M USD | −16.98M USD | −9.9M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
